TACT

Revision as of 18:08, 19 November 2013 by Rim Halaby (talk | contribs) (→‎Timeline)
Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

TACT On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of TACT

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on TACT

CDC on TACT

TACT in the news

Blogs on TACT

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for TACT

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Official Title

Trial to Assess Chelation Therapy (TACT)

Objective

The purpose of this study is to determine the safety and effectiveness of ethylene diamine tetra-acetic (EDTA) chelation therapy in individuals with coronary artery disease.

Mt. Sinai Medical Center, Miami

Timeline

Timeline
Start Date September 2003
Run-In Period August 2012
End Date October 2011
Status Completed

The previous information was derived from ClinicalTrials.gov on 11/19/2013 using the identification number NCT00044213.

Study Description

Study Description
Study Type Interventional
Study Phase Phase 3
Study Design
Allocation Randomized
Endpoint Efficacy Study
Interventional Model Factorial Assignment
Masking Double Blind (Subject, Investigator)
Study Details
Primary Purpose Treatment
Condition Coronary artery disease
Intervention EDTA <vs> EDTA placebo
High dose vitamin
High dose vitamin placebo
Study Arms Active Comparator: EDTA + high dose vitamin
Placebo Comparator: EDTA + high dose vitamin placebo
Placebo Comparator: EDTA placebo + high dose vitamin
Placebo Comparator: EDTA placebo + high dose vitamin placebo
Population Size 1708

The previous information was derived from ClinicalTrials.gov on 09/20/2013 using the identification number NCT-----.

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Outcomes

Primary Outcomes

Secondary Outcomes

Publications

Results

Conclusion

References